Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing genetically engineered allogeneic T cell product candidates for cancer and autoimmune diseases. The company is creating a pipeline of "off-the-shelf" T cell product candidates designed to target and eliminate cancer cells or pathogenic autoreactive cells in patients with autoimmune disorders. These engineered T cells are allogeneic, meaning they are derived from healthy donors for use in any patient, unlike autologous T cells which are sourced from an individual patient for their own use. This approach aims to provide readily available treatments more quickly, reliably, and at a greater scale to more patients globally. After nearly eight years of platform development and treating over 200 patients across six clinical studies, multiple clinical readouts are anticipated in the second quarter of 2026. These readouts are expected to provide validation for key scientific and clinical assumptions regarding off-the-shelf CAR T therapy, including biologic activity, safety, and the feasibility of standardized, readily available cell therapy in both oncology and autoimmune indications. The company focuses on three core programs: 1. **Large B-Cell Lymphoma (LBCL):** The ALPHA3 Trial for cemacabtagene ansegedleucel (cema-cel, previously ALLO-501A) aims to integrate this treatment into first-line (1L) LBCL treatment in community cancer centers. 2. **Autoimmune Disease (AID):** ALLO-329, a next-generation CD19 Dagger® program, emphasizes scalability and reduced or chemotherapy-free lymphodepletion to potentially transform autoimmune management. 3. **Renal Cell Carcinoma (RCC):** The TRAVERSE trial with ALLO-316 seeks to advance the Dagger® technology to optimize CAR T cell expansion and persistence, enhancing the potential of allogeneic CAR T in solid tumors. The allogeneic approach, using engineered healthy donor T cells, is intended to create an inventory of off-the-shelf products deliverable to a larger portion of eligible patients worldwide.